Stock OXIS INTERNATIONAL
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Oxis International Share Price Euronext Paris

Equities

US6918295014

Pharmaceuticals

Financials

Sales 2022 - Sales 2023 - Capitalization 10.56M 9.66M 812M
Net income 2022 -20M -18.29M -1.54B Net income 2023 -7M -6.4M -538M EV / Sales 2022 -
Net cash position 2022 16.33M 14.94M 1.26B Net cash position 2023 13.91M 12.73M 1.07B EV / Sales 2023 -
P/E ratio 2022
-1.35 x
P/E ratio 2023
-1.36 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 89.34%
More Fundamentals * Assessed data

Chart Oxis International

Dynamic Chart

Latest news about Oxis International

GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650 MT
GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study DJ
GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia CI
GT Biopharma, Inc. Announces CFO Changes CI
Top Midday Decliners MT
GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants MT
Top Premarket Gainers MT
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall MT
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia CI
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Index CI
More news

Analyst Recommendations on Oxis International

EF Hutton Starts GT Biopharma at Hold With $2 Price Target MT
HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating MT
Roth Capital Cuts GT Biopharma to Neutral From Buy, Price Target to $3 From $9 MT
B. Riley Lowers GT Biopharma's Price Target to $18 from $26 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
GT BIOPHARMA : B. Riley Raises GT Biopharma's PT to $26 from $21, Notes Steady Progress of Dose-Escalation Trial of Lead Asset GTB-3550; Keeps Buy Rating MT
More recommendations

Press releases Oxis International

GT BIOPHARMA ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR GTB-3650, AN NK CELL ENGAGER FOR TREATMENT OF CD33+ LEUKEMIA AQ
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia AQ
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules AQ
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update AQ
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results AQ
More press releases

News in other languages on Oxis International

Caterpillar deja París, el cacao está menos caliente
Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud
More news

Managers and Directors - Oxis International

Managers TitleAgeSince
Michael Breen CEO
 Chief Executive Officer 61 12/01/21
Jeffrey Miller PRN
 Corporate Officer/Principal - 13/12/22
Members of the board TitleAgeSince
Charles Casamento BRD
 Director/Board Member 78 30/04/23
Bruce Wendel BRD
 Director/Board Member 70 10/11/20
Rajesh Shrotriya BRD
 Director/Board Member 79 12/01/21
More insiders

Company Profile

GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system. The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Sector
Pharmaceuticals
Calendar
06/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.99% 848B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.64% 627B
JOHNSON & JOHNSON Stock Johnson & Johnson
+0.03% 363B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.43% 318B
ABBVIE INC. Stock AbbVie Inc.
+12.67% 299B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.51% 243B
NOVARTIS AG Stock Novartis AG
+16.72% 225B
AMGEN INC. Stock Amgen Inc.
+16.35% 179B
PFIZER, INC. Stock Pfizer, Inc.
+4.13% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GTBP Stock
  4. Stock